Relmada Therapeutics Inc (RLMD) 5.1500 $RLMD
Relmada Therapeutics Announces Issuance of U.S. Patent Covering SECUREL(TM) - an Abuse-Deterrent, Extended-Release, Technology Platform for Opioids
PR Newswire - Wed Sep 09, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that U.S. Patent No. 9,125,833 was issued by the U.S. Patent and Trademark Office (USPTO) for its patent application entitled, "Multimodal abuse resistant and extended release opioid formulations." The issued patent covers the SECUREL technology platform and Relmada's lead product candidate, LevoCap ER (REL-1015, levorphanol extended-release, abuse deterrent capsules) as well as providing additional coverage for multiple opioid molecules that are prone to abuse.
Relmada Therapeutics passes Health Canada's clearance to begin multiple ascending dose study with d-Methadone in the first half of 2016
M2 - Tue Aug 18, 3:42AM CDT
Pharmaceutical company Relmada Therapeutics (Other OTC:RLMD) disclosed on Monday the receipt of a No Objection Letter (NOL) from Health Canada to conduct a multiple ascending dose (MAD) clinical study with d-Methadone (REL-1017 dextromethadone) for the treatment of neuropathic pain.
Relmada Therapeutics Receives Health Canada Clearance to Commence Multiple Ascending Dose Study with Promising NMDA Receptor Antagonist
PR Newswire - Mon Aug 17, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has received a No Objection Letter (NOL) from Health Canada to conduct a multiple ascending dose (MAD) clinical study with d-Methadone (REL-1017 dextromethadone), its novel, N-methyl-D-aspartate (NMDA) receptor antagonist being developed for the treatment of neuropathic pain.
Relmada Therapeutics Announces Launch of New Website and Corporate Communication Channels
PR Newswire - Wed Aug 12, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD; RLMDD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today the launch of a newly formatted website featuring enhanced and readily accessible information for shareholders and other interested parties, improved navigation, and the launch of several online corporate communication channels. The new website can be accessed at www.relmada.com.
Relmada Therapeutics Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market
PR Newswire - Mon Aug 10, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that its Board of Directors has approved a 1-for-5 reverse stock split of the company's authorized, issued, and outstanding common stock in preparation for its proposed listing of its common stock on the NASDAQ Capital Market. The reverse stock split will become effective with the Financial Industry Regulatory Authority (FINRA) and in the marketplace at the open of business on August 12, 2015, whereupon the shares of common stock will begin trading on a split-adjusted basis.
Relmada Therapeutics Announces Filing of Clinical Trial Application in Canada for Multiple Ascending Dose Study with Promising NMDA Receptor Antagonist d-Methadone
PR Newswire - Mon Jul 27, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that it has filed a Clinical Trial Application (CTA) with Heath Canada to conduct a multiple ascending dose (MAD) clinical study with d-Methadone (dextromethadone, REL-1017), its novel, N-methyl-D-aspartate (NMDA) receptor antagonist being developed for the treatment of neuropathic pain.
Relmada Therapeutics hires Charles J. Casamento to board
M2 - Fri Jul 17, 5:29AM CDT
Novel therapies company Relmada Therapeutics (OtherOTC:RLMD) revealed on Thursday the election of Charles J. Casamento to its board of directors.
Relmada Therapeutics Appoints Charles J. Casamento to Its Board of Directors
PR Newswire - Thu Jul 16, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today Charles J. Casamento has joined the company's board of directors, completing the slate of three independent directors. Mr. Casamento will also serve as chairman of the audit committee for Relmada Therapeutics.
Enrollment in Relmada Therapeutics' Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine Reaches Halfway Mark
PR Newswire - Mon Jun 29, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that patient enrollment in its proof-of-concept pharmacokinetic study with novel formulations of oral, enteric-coated buprenorphine (collectively BuTab, or REL-1028) being developed for both chronic pain and opioid dependence indications has reached the halfway point. Consistent with prior guidance, the company anticipates reporting top-line results in the second half of 2015.
Relmada Therapeutics to Present at 2015 BIO International Convention
PR Newswire - Mon Jun 15, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that Sergio Traversa, chief executive officer, will present an overview of the Company at the BIO Business Forum, part of the 2015 BIO International Convention, on Wednesday, June 17, 2015, at 2:30 p.m. ET, at the Pennsylvania Convention Center, in presentation room Theater 2, Philadelphia, PA.
Postherpetic Neuralgia - Pipeline Review, H1 2015
M2 - Thu Jun 11, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hg24hw/postherpetic) has announced the addition of the "Postherpetic Neuralgia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Postherpetic Neuralgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Postherpetic Neuralgia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned - Aestus Therapeutics - Allergan - Arcion Therapeutics - Astellas Pharma - Daewoong Pharmaceutical - Daiichi Sankyo - Immune Pharmaceuticals - Intellipharmaceutics International - Merck & Co. - NeurAxon - Nuvo Research - Pfizer - Phosphagenics - Purdue Pharma - Relmada Therapeutics - Scilex Pharmaceuticals - Spinifex Pharmaceuticals - Teva Pharmaceutical Industries - Winston Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/hg...stherpetic
AGN: 295.24 (+1.64), IPCI: 2.17 (-0.01), MRK: 52.09 (-0.63), TEVA: 63.66 (+1.62), IMNP: 1.39 (+0.03)
Relmada Therapeutics Successfully Completes Phase 1 Single Ascending Dose Study with Promising NMDA Receptor Antagonist d-Methadone
PR Newswire - Wed Jun 10, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has successfully completed a Phase 1 single ascending dose (SAD) clinical study with d-Methadone (dextromethadone, REL-1017), its novel, N-methyl-D-aspartate (NMDA) receptor antagonist being developed for the treatment of neuropathic pain.
Global Opium (Opioid) Addiction Pipeline Review, H1 2015 - 15 Companies & 20 Drug Profiles
M2 - Wed Jun 10, 6:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hhxtt9/opium_opioid) has announced the addition of the "Opium (Opioid) Addiction - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Opium (Opioid) Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acura Pharmaceuticals, Inc. - Alkermes Plc - BioDelivery Sciences International, Inc. - Camurus AB - Celtic Pharmaceutical Holdings L.P. - D&A Pharma SAS - Foresee Pharmaceuticals, LLC - Heron Therapeutics, Inc. - Indivior PLC - INSYS Therapeutics, Inc. - Omeros Corporation - Pfizer Inc. - Relmada Therapeutics, Inc. - Titan Pharmaceuticals, Inc. - Zynerba Pharmaceuticals, Inc. Drug Profiles - (buprenorphine hydrochloride naloxone hydrochloride) - Buprenorphine Hemiadipate Hydrochloride - buprenorphine hydrochloride - buprenorphine hydrochloride depot - buprenorphine hydrochloride ER - buprenorphine hydrochloride long acting - buprenorphine hydrochloride SR - cannabidiol - FP-004 - MAL - methadone IR - naltrexone - naltrexone - OMS-405 - OMS-527 - PF-5006739 - samidorphan - Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction - TA-CD - Vaccine for Opium Addiction For more information visit http://www.researchandmarkets.com/research/hh...ium_opioid
BDSI: 7.03 (-0.06), INSY: 36.20 (+0.23), HRTX: 37.94 (-0.45), PFE: 32.97 (+0.35), ALKS: 70.95 (+1.28), ACUR: 3.13 (-0.11), OMER: 14.12 (+0.33)
Relmada Therapeutics, Inc. - Product Pipeline Review - 2014
M2 - Thu May 28, 6:31AM CDT
Product Pipeline Review - 2014
Relmada Therapeutics to Present at the 2015 LD Micro Invitational Conference
PR Newswire - Wed May 27, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it will present at the 2015 LD Micro Invitational Conference on Monday, June 1, 2015 at the Luxe Sunset Hotel in Bel Air, California.
Relmada Therapeutics to Present at the 2015 Marcum MicroCap Conference
PR Newswire - Tue May 19, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it will present at the 2015 Marcum MicroCap Conference on Thursday, May 28, 2015 in New York City at the Grand Hyatt Hotel.
Addiction Pipeline Review 2015
M2 - Thu May 14, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mhcllx/addiction) has announced the addition of the "Addiction - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Acura Pharmaceuticals, Inc. - Aradigm Corporation - Arena Pharmaceuticals, Inc. - Astraea Therapeutics, LLC - AstraZeneca PLC - Beech Tree Labs, Inc. - BioDelivery Sciences International, Inc. - Bionex Pharmaceuticals LLC - Eli Lilly and Company - Embera NeuroTherapeutics, Inc. - Euthymics Bioscience, Inc. - Foresee Pharmaceuticals, LLC - FORUM Pharmaceuticals Inc. - Gilead Sciences, Inc. - GlaxoSmithKline plc - Grunenthal GmbH - Heptares Therapeutics Ltd. - Immunovaccine, Inc. - Indivior PLC - INSYS Therapeutics, Inc. - Invion Limited - Johnson & Johnson - Pfizer Inc. - Relmada Therapeutics, Inc. - Rottapharm SpA - Royalty Pharma - Selecta Biosciences, Inc. - SK Biopharmaceuticals Co., Ltd. - Sun Pharma Advanced Research Company Ltd. - Targacept, Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/mhcllx/addiction
BDSI: 7.03 (-0.06), PFE: 32.97 (+0.35), LLY: 81.80 (+0.96), GSK: 40.26 (+0.02), ACUR: 3.13 (-0.11), JNJ: 92.93 (+0.21), INSY: 36.20 (+0.23), TRGT: 0.96 (-1.25), GILD: 109.63 (+2.38), AZN: 33.30 (+0.02), ABBV: 59.35 (-0.23), ARNA: 2.86 (+0.15)
Relmada Therapeutics announces USPTO's patent allowance for proprietary SECUREL abuse deterrent technology platform
M2 - Wed May 13, 4:34AM CDT
Pharmaceutical company Relmada Therapeutics (OtherOTC:RLMD) disclosed on Tuesday that its new patent relating to its proprietary SECUREL abuse deterrent technology platform was allowed for issuance by the US Patent and Trademark Office (USPTO).
Relmada Therapeutics Announces Notice of Allowance for U.S. Patent Covering SECUREL(TM), its Abuse-Deterrent, Extended-Release, Technology Platform for Opioids
PR Newswire - Tue May 12, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that Application No. 12/597,702 relating to its proprietary SECUREL abuse deterrent technology platform was allowed for issuance as a new patent by the U.S. Patent and Trademark Office (USPTO).
Global Insulin Patch Market Opportunity Analysis 2015
M2 - Wed May 06, 5:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rkj3v9/global_insulin) has announced the addition of the "Global Insulin Patch Market Opportunity Analysis" report to their offering. Highly advanced technology like ultrasound and iontophoresis are being used for the development of modern insulin patches. Depending upon the type of technique, their prices may vary which may be out of reach of several patients. In long-term, it would be considered as inexpensive but high upfront cost may deter some diabetic patients. Benefits like greater control over blood glucose levels and ease of utilization are one of the most significant benefits of these technologies. It is expected that investigators would also explore the techniques like electroporation, thermal ablation and microdermabrasion for making insulin patches. These techniques are expected to increase the cost effectiveness due to which their market penetration would increase. In coming years, it is expected that investigators would be able to come forth with insulin patches having higher pharmacological benefits with lesser prices. Besides this, newer modalities are also expected to be developed due to which more sales are expected to be generated. Development of insulin patches are expected to pave the path for the development of large molecule based transdermal patches. This is going to be a major technological success due to which large number of patients would get more therapeutic benefits. Due to increased indications, more revenues are expected to generate from this field. Both molecules and formulations have to be revisited that will lead to new innovations. Moreover, pharmaceutical companies engaged in the production of insulin patches may venture in other diseases segment by using same technology. Insulin patches have yet not made place in global market but they will definitely encourage the other pharmaceutical companies to follow the lead. Pharmaceutical companies are expected to launch the first insulin patch in global market in next few years. "Global Insulin Patch Market Opportunity Analysis" Report Highlights: - Introduction to Insulin Patch - Mechanism Iontophoresis, Ultrasonic & Microneedle Insulin Patch - Global Insulin Patch Market Analysis - Global Insulin Patch Clinical Pipeline by Company, Indication & Phase - Global Insulin Patch Clinical Pipeline: 9 Patches - Highest Phase of Insulin Patch Development: Phase-II - Insulin Patch Patent Analysis Key Topics Covered: 1. Introduction to Insulin Patch 2. Comparison between Insulin Patches & Other Insulin Modalities 3. Mechanism of Insulin Patches 4. Emerging Trends in Insulin Delivery 5. Global Insulin Patch Market Analysis 6. Global Insulin Patch Market Dynamics 7. Future Prospects of Insulin Patch Market 8. Global Insulin Patch Clinical Pipeline by Company, Indication & Phase 9. Discontinued Insulin Patch in Clinical Pipeline 10. Competitive Landscape - Dermisonics - Encapsulation Systems - Encapsulife - Mesoblast - NeurogesX - NOLabs AB - Novo Nordisk - Phosphagenics - Relmada Therapeutics - Zosano Pharma For more information visit http://www.researchandmarkets.com/research/rk...al_insulin
NVO: 56.95 (+0.37), ZSAN: 7.97 (+0.05)
Relmada Therapeutics Announces Issuance of U.S. Patent Covering SECUREL(TM) - an Abuse-Deterrent, Extended-Release, Technology Platform for Opioids
PR Newswire - Wed Sep 09, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that U.S. Patent No. 9,125,833 was issued by the U.S. Patent and Trademark Office (USPTO) for its patent application entitled, "Multimodal abuse resistant and extended release opioid formulations." The issued patent covers the SECUREL technology platform and Relmada's lead product candidate, LevoCap ER (REL-1015, levorphanol extended-release, abuse deterrent capsules) as well as providing additional coverage for multiple opioid molecules that are prone to abuse.
Relmada Therapeutics passes Health Canada's clearance to begin multiple ascending dose study with d-Methadone in the first half of 2016
M2 - Tue Aug 18, 3:42AM CDT
Pharmaceutical company Relmada Therapeutics (Other OTC:RLMD) disclosed on Monday the receipt of a No Objection Letter (NOL) from Health Canada to conduct a multiple ascending dose (MAD) clinical study with d-Methadone (REL-1017 dextromethadone) for the treatment of neuropathic pain.
Relmada Therapeutics Receives Health Canada Clearance to Commence Multiple Ascending Dose Study with Promising NMDA Receptor Antagonist
PR Newswire - Mon Aug 17, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has received a No Objection Letter (NOL) from Health Canada to conduct a multiple ascending dose (MAD) clinical study with d-Methadone (REL-1017 dextromethadone), its novel, N-methyl-D-aspartate (NMDA) receptor antagonist being developed for the treatment of neuropathic pain.
Relmada Therapeutics Announces Launch of New Website and Corporate Communication Channels
PR Newswire - Wed Aug 12, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD; RLMDD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today the launch of a newly formatted website featuring enhanced and readily accessible information for shareholders and other interested parties, improved navigation, and the launch of several online corporate communication channels. The new website can be accessed at www.relmada.com.
Relmada Therapeutics Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market
PR Newswire - Mon Aug 10, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that its Board of Directors has approved a 1-for-5 reverse stock split of the company's authorized, issued, and outstanding common stock in preparation for its proposed listing of its common stock on the NASDAQ Capital Market. The reverse stock split will become effective with the Financial Industry Regulatory Authority (FINRA) and in the marketplace at the open of business on August 12, 2015, whereupon the shares of common stock will begin trading on a split-adjusted basis.
Relmada Therapeutics Announces Filing of Clinical Trial Application in Canada for Multiple Ascending Dose Study with Promising NMDA Receptor Antagonist d-Methadone
PR Newswire - Mon Jul 27, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that it has filed a Clinical Trial Application (CTA) with Heath Canada to conduct a multiple ascending dose (MAD) clinical study with d-Methadone (dextromethadone, REL-1017), its novel, N-methyl-D-aspartate (NMDA) receptor antagonist being developed for the treatment of neuropathic pain.
Relmada Therapeutics hires Charles J. Casamento to board
M2 - Fri Jul 17, 5:29AM CDT
Novel therapies company Relmada Therapeutics (OtherOTC:RLMD) revealed on Thursday the election of Charles J. Casamento to its board of directors.
Relmada Therapeutics Appoints Charles J. Casamento to Its Board of Directors
PR Newswire - Thu Jul 16, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today Charles J. Casamento has joined the company's board of directors, completing the slate of three independent directors. Mr. Casamento will also serve as chairman of the audit committee for Relmada Therapeutics.
Enrollment in Relmada Therapeutics' Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine Reaches Halfway Mark
PR Newswire - Mon Jun 29, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that patient enrollment in its proof-of-concept pharmacokinetic study with novel formulations of oral, enteric-coated buprenorphine (collectively BuTab, or REL-1028) being developed for both chronic pain and opioid dependence indications has reached the halfway point. Consistent with prior guidance, the company anticipates reporting top-line results in the second half of 2015.
Relmada Therapeutics to Present at 2015 BIO International Convention
PR Newswire - Mon Jun 15, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that Sergio Traversa, chief executive officer, will present an overview of the Company at the BIO Business Forum, part of the 2015 BIO International Convention, on Wednesday, June 17, 2015, at 2:30 p.m. ET, at the Pennsylvania Convention Center, in presentation room Theater 2, Philadelphia, PA.
Postherpetic Neuralgia - Pipeline Review, H1 2015
M2 - Thu Jun 11, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hg24hw/postherpetic) has announced the addition of the "Postherpetic Neuralgia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Postherpetic Neuralgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Postherpetic Neuralgia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned - Aestus Therapeutics - Allergan - Arcion Therapeutics - Astellas Pharma - Daewoong Pharmaceutical - Daiichi Sankyo - Immune Pharmaceuticals - Intellipharmaceutics International - Merck & Co. - NeurAxon - Nuvo Research - Pfizer - Phosphagenics - Purdue Pharma - Relmada Therapeutics - Scilex Pharmaceuticals - Spinifex Pharmaceuticals - Teva Pharmaceutical Industries - Winston Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/hg...stherpetic
AGN: 295.24 (+1.64), IPCI: 2.17 (-0.01), MRK: 52.09 (-0.63), TEVA: 63.66 (+1.62), IMNP: 1.39 (+0.03)
Relmada Therapeutics Successfully Completes Phase 1 Single Ascending Dose Study with Promising NMDA Receptor Antagonist d-Methadone
PR Newswire - Wed Jun 10, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has successfully completed a Phase 1 single ascending dose (SAD) clinical study with d-Methadone (dextromethadone, REL-1017), its novel, N-methyl-D-aspartate (NMDA) receptor antagonist being developed for the treatment of neuropathic pain.
Global Opium (Opioid) Addiction Pipeline Review, H1 2015 - 15 Companies & 20 Drug Profiles
M2 - Wed Jun 10, 6:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hhxtt9/opium_opioid) has announced the addition of the "Opium (Opioid) Addiction - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Opium (Opioid) Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acura Pharmaceuticals, Inc. - Alkermes Plc - BioDelivery Sciences International, Inc. - Camurus AB - Celtic Pharmaceutical Holdings L.P. - D&A Pharma SAS - Foresee Pharmaceuticals, LLC - Heron Therapeutics, Inc. - Indivior PLC - INSYS Therapeutics, Inc. - Omeros Corporation - Pfizer Inc. - Relmada Therapeutics, Inc. - Titan Pharmaceuticals, Inc. - Zynerba Pharmaceuticals, Inc. Drug Profiles - (buprenorphine hydrochloride naloxone hydrochloride) - Buprenorphine Hemiadipate Hydrochloride - buprenorphine hydrochloride - buprenorphine hydrochloride depot - buprenorphine hydrochloride ER - buprenorphine hydrochloride long acting - buprenorphine hydrochloride SR - cannabidiol - FP-004 - MAL - methadone IR - naltrexone - naltrexone - OMS-405 - OMS-527 - PF-5006739 - samidorphan - Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction - TA-CD - Vaccine for Opium Addiction For more information visit http://www.researchandmarkets.com/research/hh...ium_opioid
BDSI: 7.03 (-0.06), INSY: 36.20 (+0.23), HRTX: 37.94 (-0.45), PFE: 32.97 (+0.35), ALKS: 70.95 (+1.28), ACUR: 3.13 (-0.11), OMER: 14.12 (+0.33)
Relmada Therapeutics, Inc. - Product Pipeline Review - 2014
M2 - Thu May 28, 6:31AM CDT
Product Pipeline Review - 2014
Relmada Therapeutics to Present at the 2015 LD Micro Invitational Conference
PR Newswire - Wed May 27, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it will present at the 2015 LD Micro Invitational Conference on Monday, June 1, 2015 at the Luxe Sunset Hotel in Bel Air, California.
Relmada Therapeutics to Present at the 2015 Marcum MicroCap Conference
PR Newswire - Tue May 19, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it will present at the 2015 Marcum MicroCap Conference on Thursday, May 28, 2015 in New York City at the Grand Hyatt Hotel.
Addiction Pipeline Review 2015
M2 - Thu May 14, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mhcllx/addiction) has announced the addition of the "Addiction - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Acura Pharmaceuticals, Inc. - Aradigm Corporation - Arena Pharmaceuticals, Inc. - Astraea Therapeutics, LLC - AstraZeneca PLC - Beech Tree Labs, Inc. - BioDelivery Sciences International, Inc. - Bionex Pharmaceuticals LLC - Eli Lilly and Company - Embera NeuroTherapeutics, Inc. - Euthymics Bioscience, Inc. - Foresee Pharmaceuticals, LLC - FORUM Pharmaceuticals Inc. - Gilead Sciences, Inc. - GlaxoSmithKline plc - Grunenthal GmbH - Heptares Therapeutics Ltd. - Immunovaccine, Inc. - Indivior PLC - INSYS Therapeutics, Inc. - Invion Limited - Johnson & Johnson - Pfizer Inc. - Relmada Therapeutics, Inc. - Rottapharm SpA - Royalty Pharma - Selecta Biosciences, Inc. - SK Biopharmaceuticals Co., Ltd. - Sun Pharma Advanced Research Company Ltd. - Targacept, Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/mhcllx/addiction
BDSI: 7.03 (-0.06), PFE: 32.97 (+0.35), LLY: 81.80 (+0.96), GSK: 40.26 (+0.02), ACUR: 3.13 (-0.11), JNJ: 92.93 (+0.21), INSY: 36.20 (+0.23), TRGT: 0.96 (-1.25), GILD: 109.63 (+2.38), AZN: 33.30 (+0.02), ABBV: 59.35 (-0.23), ARNA: 2.86 (+0.15)
Relmada Therapeutics announces USPTO's patent allowance for proprietary SECUREL abuse deterrent technology platform
M2 - Wed May 13, 4:34AM CDT
Pharmaceutical company Relmada Therapeutics (OtherOTC:RLMD) disclosed on Tuesday that its new patent relating to its proprietary SECUREL abuse deterrent technology platform was allowed for issuance by the US Patent and Trademark Office (USPTO).
Relmada Therapeutics Announces Notice of Allowance for U.S. Patent Covering SECUREL(TM), its Abuse-Deterrent, Extended-Release, Technology Platform for Opioids
PR Newswire - Tue May 12, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that Application No. 12/597,702 relating to its proprietary SECUREL abuse deterrent technology platform was allowed for issuance as a new patent by the U.S. Patent and Trademark Office (USPTO).
Global Insulin Patch Market Opportunity Analysis 2015
M2 - Wed May 06, 5:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rkj3v9/global_insulin) has announced the addition of the "Global Insulin Patch Market Opportunity Analysis" report to their offering. Highly advanced technology like ultrasound and iontophoresis are being used for the development of modern insulin patches. Depending upon the type of technique, their prices may vary which may be out of reach of several patients. In long-term, it would be considered as inexpensive but high upfront cost may deter some diabetic patients. Benefits like greater control over blood glucose levels and ease of utilization are one of the most significant benefits of these technologies. It is expected that investigators would also explore the techniques like electroporation, thermal ablation and microdermabrasion for making insulin patches. These techniques are expected to increase the cost effectiveness due to which their market penetration would increase. In coming years, it is expected that investigators would be able to come forth with insulin patches having higher pharmacological benefits with lesser prices. Besides this, newer modalities are also expected to be developed due to which more sales are expected to be generated. Development of insulin patches are expected to pave the path for the development of large molecule based transdermal patches. This is going to be a major technological success due to which large number of patients would get more therapeutic benefits. Due to increased indications, more revenues are expected to generate from this field. Both molecules and formulations have to be revisited that will lead to new innovations. Moreover, pharmaceutical companies engaged in the production of insulin patches may venture in other diseases segment by using same technology. Insulin patches have yet not made place in global market but they will definitely encourage the other pharmaceutical companies to follow the lead. Pharmaceutical companies are expected to launch the first insulin patch in global market in next few years. "Global Insulin Patch Market Opportunity Analysis" Report Highlights: - Introduction to Insulin Patch - Mechanism Iontophoresis, Ultrasonic & Microneedle Insulin Patch - Global Insulin Patch Market Analysis - Global Insulin Patch Clinical Pipeline by Company, Indication & Phase - Global Insulin Patch Clinical Pipeline: 9 Patches - Highest Phase of Insulin Patch Development: Phase-II - Insulin Patch Patent Analysis Key Topics Covered: 1. Introduction to Insulin Patch 2. Comparison between Insulin Patches & Other Insulin Modalities 3. Mechanism of Insulin Patches 4. Emerging Trends in Insulin Delivery 5. Global Insulin Patch Market Analysis 6. Global Insulin Patch Market Dynamics 7. Future Prospects of Insulin Patch Market 8. Global Insulin Patch Clinical Pipeline by Company, Indication & Phase 9. Discontinued Insulin Patch in Clinical Pipeline 10. Competitive Landscape - Dermisonics - Encapsulation Systems - Encapsulife - Mesoblast - NeurogesX - NOLabs AB - Novo Nordisk - Phosphagenics - Relmada Therapeutics - Zosano Pharma For more information visit http://www.researchandmarkets.com/research/rk...al_insulin
NVO: 56.95 (+0.37), ZSAN: 7.97 (+0.05)
